JP6039585B2 - Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物 - Google Patents

Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物 Download PDF

Info

Publication number
JP6039585B2
JP6039585B2 JP2013555610A JP2013555610A JP6039585B2 JP 6039585 B2 JP6039585 B2 JP 6039585B2 JP 2013555610 A JP2013555610 A JP 2013555610A JP 2013555610 A JP2013555610 A JP 2013555610A JP 6039585 B2 JP6039585 B2 JP 6039585B2
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
formula
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013555610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509322A5 (https=
JP2014509322A (ja
Inventor
ジェイムズ エフ. ブレイク,
ジェイムズ エフ. ブレイク,
ロバート カーク デライル,
ロバート カーク デライル,
ミース, リサ エー. デ
ミース, リサ エー. デ
ジェイムズ エム. グラハム,
ジェイムズ エム. グラハム,
フルー, イバン ル
フルー, イバン ル
マイケル リオン,
マイケル リオン,
ジョン イー. ロビンソン,
ジョン イー. ロビンソン,
エリ エム. ウォレス,
エリ エム. ウォレス,
ビン ワン,
ビン ワン,
ルイ スー,
ルイ スー,
Original Assignee
アレイ バイオファーマ、インコーポレイテッド
アレイ バイオファーマ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ、インコーポレイテッド, アレイ バイオファーマ、インコーポレイテッド filed Critical アレイ バイオファーマ、インコーポレイテッド
Publication of JP2014509322A publication Critical patent/JP2014509322A/ja
Publication of JP2014509322A5 publication Critical patent/JP2014509322A5/ja
Application granted granted Critical
Publication of JP6039585B2 publication Critical patent/JP6039585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013555610A 2011-02-25 2012-02-24 Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物 Expired - Fee Related JP6039585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446902P 2011-02-25 2011-02-25
US61/446,902 2011-02-25
PCT/US2012/026572 WO2012154274A1 (en) 2011-02-25 2012-02-24 Triazolopyridine compounds as pim kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016032675A Division JP2016106118A (ja) 2011-02-25 2016-02-24 Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物

Publications (3)

Publication Number Publication Date
JP2014509322A JP2014509322A (ja) 2014-04-17
JP2014509322A5 JP2014509322A5 (https=) 2015-04-09
JP6039585B2 true JP6039585B2 (ja) 2016-12-07

Family

ID=46000320

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013555610A Expired - Fee Related JP6039585B2 (ja) 2011-02-25 2012-02-24 Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物
JP2016032675A Withdrawn JP2016106118A (ja) 2011-02-25 2016-02-24 Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016032675A Withdrawn JP2016106118A (ja) 2011-02-25 2016-02-24 Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物

Country Status (32)

Country Link
US (1) US8889704B2 (https=)
EP (1) EP2678329B1 (https=)
JP (2) JP6039585B2 (https=)
KR (1) KR101940338B1 (https=)
CN (1) CN103492377B (https=)
AR (1) AR085489A1 (https=)
AU (1) AU2012254082B2 (https=)
BR (1) BR112013021675A2 (https=)
CA (1) CA2828269C (https=)
CL (1) CL2013002446A1 (https=)
CO (1) CO6771441A2 (https=)
CR (1) CR20130460A (https=)
CY (1) CY1117197T1 (https=)
DK (1) DK2678329T3 (https=)
ES (1) ES2563152T3 (https=)
HR (1) HRP20160134T1 (https=)
HU (1) HUE027675T2 (https=)
IL (1) IL228108A (https=)
ME (1) ME02365B (https=)
MX (1) MX339899B (https=)
PH (1) PH12013501754A1 (https=)
PL (1) PL2678329T3 (https=)
RS (1) RS54586B1 (https=)
RU (1) RU2598846C2 (https=)
SG (1) SG192944A1 (https=)
SI (1) SI2678329T1 (https=)
SM (1) SMT201600052B (https=)
TW (1) TWI529170B (https=)
UA (1) UA111075C2 (https=)
UY (1) UY33924A (https=)
WO (1) WO2012154274A1 (https=)
ZA (1) ZA201306997B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
RU2014145806A (ru) * 2012-04-25 2016-06-10 Ф. Хоффманн-Ля Рош Аг Способы производства (3,4-дихлорфенил)-((s)-3-пропил-пирролидин-3-ил)-метанонгидрохлорида
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
MA45122A (fr) * 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CN117838695A (zh) 2018-04-13 2024-04-09 住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
CA3106470A1 (en) 2018-07-17 2020-01-23 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种(3r,4s)-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种(3s,4r)-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
US20220056043A1 (en) * 2019-02-19 2022-02-24 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof
JPWO2020203609A1 (https=) 2019-03-29 2020-10-08
CN111171023B (zh) * 2020-01-10 2021-12-21 中国药科大学 一种具有Pim1抑制活性的化合物及其制备方法与医药用途
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390217A (zh) 1999-11-12 2003-01-08 神经原公司 二环和三环杂芳族化合物
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
WO2001083481A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
EE200300437A (et) 2001-03-09 2004-02-16 Pfizer Products Inc. Triasolopüridiinid kui põletikuvastased ained
US7227006B2 (en) 2002-01-19 2007-06-05 Sanofi-Aventis Deutschland Gmbh PIM-3 kinase as a target for type 2 diabetes mellitus
WO2004058769A2 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
BRPI0514391A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
JP2008521858A (ja) 2004-12-01 2008-06-26 ラボラトワール セローノ ソシエテ アノニム 過増殖性疾患を処置するための[1,2,4]トリアゾロ[4,3−a]ピリジン誘導体
US8053454B2 (en) 2005-10-06 2011-11-08 Exelixis, Inc. Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
JP2009523820A (ja) 2006-01-23 2009-06-25 アミラ ファーマシューティカルス,インコーポレーテッド 5−リポキシゲナーゼの三環系抑制剤
AR061229A1 (es) 2006-06-06 2008-08-13 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa
BRPI0718029A2 (pt) 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
CN101674827A (zh) * 2007-03-02 2010-03-17 先灵公司 苯并咪唑衍生物及其使用方法
US20100144751A1 (en) * 2007-03-28 2010-06-10 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
EP2137184B1 (en) * 2007-04-03 2013-05-08 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為pim激酶抑制劑之三唑吡啶化合物
WO2010039825A2 (en) * 2008-10-01 2010-04-08 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
WO2010111058A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
UA111075C2 (uk) 2016-03-25
CA2828269C (en) 2019-01-15
SMT201600052B (it) 2016-04-29
KR101940338B1 (ko) 2019-01-18
HK1190714A1 (zh) 2014-07-11
WO2012154274A1 (en) 2012-11-15
SI2678329T1 (sl) 2016-05-31
JP2016106118A (ja) 2016-06-16
CR20130460A (es) 2013-10-16
RU2013143292A (ru) 2015-04-10
NZ615300A (en) 2014-12-24
RS54586B1 (sr) 2016-08-31
AU2012254082A1 (en) 2013-09-26
CN103492377B (zh) 2016-04-20
HUE027675T2 (en) 2016-11-28
KR20140021577A (ko) 2014-02-20
EP2678329B1 (en) 2015-11-18
HRP20160134T1 (hr) 2016-04-08
BR112013021675A2 (pt) 2016-11-01
DK2678329T3 (da) 2016-02-22
US8889704B2 (en) 2014-11-18
AR085489A1 (es) 2013-10-09
US20140005213A1 (en) 2014-01-02
PH12013501754A1 (en) 2013-10-14
SG192944A1 (en) 2013-09-30
IL228108A0 (en) 2013-09-30
MX2013009820A (es) 2014-09-01
IL228108A (en) 2017-07-31
JP2014509322A (ja) 2014-04-17
ME02365B (me) 2016-06-20
UY33924A (es) 2013-09-30
CY1117197T1 (el) 2017-04-05
TW201245193A (en) 2012-11-16
PL2678329T3 (pl) 2016-06-30
CA2828269A1 (en) 2012-11-15
AU2012254082B2 (en) 2016-12-08
MX339899B (es) 2016-06-16
CN103492377A (zh) 2014-01-01
EP2678329A1 (en) 2014-01-01
ES2563152T3 (es) 2016-03-11
CO6771441A2 (es) 2013-10-15
TWI529170B (zh) 2016-04-11
RU2598846C2 (ru) 2016-09-27
CL2013002446A1 (es) 2014-04-11
ZA201306997B (en) 2015-05-27

Similar Documents

Publication Publication Date Title
JP6039585B2 (ja) Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物
EP2334677B1 (en) Triazolopyridine compounds as pim kinase inhibitors
JP7721501B2 (ja) Cd38の阻害剤としてのヘテロ二環式アミド
JP2020200338A (ja) Pimキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
US20100144751A1 (en) IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
HK1190714B (en) Triazolopyridine compounds as pim kinase inhibitors
US8987251B2 (en) Triazolopyridine compounds as PIM kinase inhibitors
NZ615300B2 (en) Triazolopyridine compounds as pim kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161104

R150 Certificate of patent or registration of utility model

Ref document number: 6039585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees